(rac)-2-amino-1-(p-tolyl)propan-1-one hydrochloride | 6941-17-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (rac)-2-amino-1-(p-tolyl)propan-1-one hydrochloride
• 英文别名: 2-amino-1-p-tolyl-propan-1-one; hydrochloride；2-Amino-1-p-tolyl-propan-1-on; Hydrochlorid；2-amino-4'-methylpropiophenone hydrochloride；α-Amino-4-methyl-propiophenon；2-Amino-1-(4-methylphenyl)propan-1-one hydrochloride；2-amino-1-(4-methylphenyl)propan-1-one;hydrochloride
• CAS: 6941-17-9
• 化学式: C₁₀H₁₃NO*ClH
• 分子量: 199.68
• InChiKey: FZNOSALCDVTESF-UHFFFAOYSA-N

物化性质

• 熔点：
  >168°C (dec.)
• 溶解度：
  甲醇（微溶）、水（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  1.95
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (rac)-2-amino-1-(p-tolyl)propan-1-one hydrochloride 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成 2-amino-1-(4-methylphenyl)-1-propanol
  参考文献：
  名称：

  MAO inhibition by arylisopropylamines: the effect of oxygen substituents at the β-position

  摘要：

  Twenty-nine arylisopropylamines, substituted at the beta-position of their side chain by an oxo, hydroxy, or methoxy group, were evaluated in vitro as MAO-A and MAO-B inhibitors. The oxo derivatives ('cathinones') were in general less active as MAO-A inhibitors than the corresponding arylisopropylamines, but exhibited an interesting MAO-13 inhibiting activity, which was absent in the hydroxy, methoxy, and beta-unsubstituted analogues. These results suggest that selective affinity for the two MAO isoforms in this family of compounds is modulated not only by the aryl substitution pattern but also by the side-chain substituents on the aryl-alkylamine scaffold. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.033
• 作为产物：
  描述：

  2-氯-1-(4-甲基苯基)-(9ci)-1-丙酮 在 盐酸 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.0h， 生成 (rac)-2-amino-1-(p-tolyl)propan-1-one hydrochloride
  参考文献：
  名称：

  Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters

  摘要：

  Background and Purpose4‐Methyl‐N‐methylcathinone (mephedrone) is a synthetic stimulant that acts as a substrate‐type releaser at transporters for dopamine (DAT), noradrenaline (NET) and 5‐HT (SERT). Upon systemic administration, mephedrone is metabolized to several phase I compounds: the N‐demethylated metabolite, 4‐methylcathinone (nor‐mephedrone); the ring‐hydroxylated metabolite, 4‐hydroxytolylmephedrone (4‐OH‐mephedrone); and the reduced keto‐metabolite, dihydromephedrone.Experimental ApproachWe used in vitro assays to compare the effects of mephedrone and synthetically prepared metabolites on transporter‐mediated uptake and release in HEK293 cells expressing human monoamine transporters and in rat brain synaptosomes. In vivo microdialysis was employed to examine the effects of i.v. metabolite injection (1 and 3 mg·kg−1) on extracellular dopamine and 5‐HT levels in rat nucleus accumbens.Key ResultsIn cells expressing transporters, mephedrone and its metabolites inhibited uptake, although dihydromephedrone was weak overall. In cells and synaptosomes, nor‐mephedrone and 4‐OH‐mephedrone served as transportable substrates, inducing release via monoamine transporters. When administered to rats, mephedrone and nor‐mephedrone produced elevations in extracellular dopamine and 5‐HT, whereas 4‐OH‐mephedrone did not. Mephedrone and nor‐mephedrone, but not 4‐OH‐mephedrone, induced locomotor activity.Conclusions and ImplicationsOur results demonstrate that phase I metabolites of mephedrone are transporter substrates (i.e. releasers) at DAT, NET and SERT, but dihydromephedrone is weak in this regard. When administered in vivo, nor‐mephedrone increases extracellular dopamine and 5‐HT in the brain whereas 4‐OH‐mephedrone does not, suggesting the latter metabolite does not penetrate the blood–brain barrier. Future studies should examine the pharmacokinetics of nor‐mephedrone to determine its possible contribution to the in vivo effects produced by mephedrone.

  DOI：

  10.1111/bph.13547

文献信息

• Triazine derivatives, and pharmaceutical compositions comprising the same
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04616014A1

  公开（公告）日：1986-10-07

  New triazine derivatives represented by the formula: ##STR1## wherein R.sup.1 is aryl, pyridyl, thienyl, 1,2,3,4-tetrahydroquinolyl or 1,3,4,5-tetrahydro-2H-1-benzazepinyl, optionally substituted with lower alkyl, lower alkoxy, halogen, nitro or oxo, R.sup.2 is hydrogen, lower alkyl or carbamoyl substituted with lower alkyl or ar(lower)alkyl, and Z is a group selected from ##STR2## and pharmaceutically acceptable salt thereof, processes for preparation thereof and pharmaceutical compositions comprising the same of antihypertensive and antithrombotic activity.

  新的三嗪衍生物的化学式如下：##STR1## 其中 R.sup.1 是芳基、吡啶基、噻吩基、1,2,3,4-四氢喹啉基或1,3,4,5-四氢-2H-1-苯并氮杂环基，可选择地取代为较低的烷基、较低的烷氧基、卤素、硝基或氧代基，R.sup.2 是氢、较低的烷基或羰胺基，其被较低的烷基或芳基(烷基)取代，Z 是从##STR2## 中选择的基团及其药学上可接受的盐，以及制备这些化合物的方法和包含具有抗高血压和抗血栓活性的相同药物组合物。
• Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0077983A1

  公开（公告）日：1983-05-04

  New triazine derivatives represented by the formula: wherein R1 is aryl, pyridyl, thienyl, 1,2,3,4-tetrahydroquinolyl or 1,3,4,5-tetrahydro-2H-1-benzazepinyl, optionally substituted with lower alkyl, lower alkoxy, halogen, nitro or oxo; R2 is hydrogen, lower alkyl or carbamoyl substituted with lower alkyl or ar(lower)alkyl; and Z is a group selected from and pharmaceutically acceptable salt thereof, processes for preparation thereof and pharmaceutical compositions comprising the same.

  由以下式子表示的新型三嗪衍生物 其中 R1 是芳基、吡啶基、噻吩基、1,2,3,4-四氢喹喔啉基或 1,3,4,5-四氢-2H-1-苯并氮杂卓基，可选择被低级烷基、低级烷氧基、卤素、硝基或氧代取代； R2 是氢、低级烷基或被低级烷基或芳基（低级）烷基取代的氨基甲酰基；以及 Z 是选自以下的基团 及其药学上可接受的盐、制备工艺和包含这些物质的药物组合物。
• 5-Aryl-imidazolin-2-ones as a scaffold for potent antioxidant and memory-improving activity
  作者：Kazutoshi Watanabe、Yasuhiro Morinaka、Yoshio Hayashi、Masaki Shinoda、Hiroyoshi Nishi、Nobuko Fukushima、Toshiaki Watanabe、Akira Ishibashi、Satoshi Yuki、Masahiko Tanaka

  DOI：10.1016/j.bmcl.2007.12.064

  日期：2008.2

  A series of 5-phenyl-substituted-N-alkyl-imidazolin-2-ones with potent radical-scavenging activity and lipid peroxidation inhibitory activity was synthesized. Many of the compounds showed memory-improving effect in animal models independent of the inhibitory activity on lipid peroxidation. (c) 2008 Elsevier Ltd. All rights reserved.
• Tiffeneau; Levy; Ditz, Bulletin de la Societe Chimique de France, 1935, vol. <5> 2, p. 1855,1862
  作者：Tiffeneau、Levy、Ditz

  DOI：——

  日期：——
• US4616014A
  申请人：——

  公开号：US4616014A

  公开（公告）日：1986-10-07